Skip to main content
. Author manuscript; available in PMC: 2013 Oct 4.
Published in final edited form as: Oncogene. 2012 May 21;32(14):1794–1810. doi: 10.1038/onc.2012.200

Fig. 4.

Fig. 4

Effects of chemicals on RSK4 splicing. A: Treatment of Panc28 and MCF15 cells with indolocarbazole-derivatives NPCD and Trib-B, structures of which are shown, induces splicing at the 39th nt of exon 21, as detected by RT-PCR with the hF1791+mR2720 primers (1st panel), while the total hRSK4 mRNA level is slightly induced, compared with the treatment with the vehicle, DMSO (2nd panel). B: Treatment of the MCF15 and MB231 human cells (1st panel) as well as the M8 mouse cells (2nd panel) with 5-Aza decreases the level of the ΔE21 or ΔE24 variants while slightly increases the level of the intact RSK4. 5-Aza treatment does not affect the splicing at the 15th nt of E22 of mRSK4 (3rd panel). C: Treatment with cisplatin for two days does not obviously affect splicing at the 15th nt of E22 in 4T1 and 4T07 cells (left panel) but it affects the splicing at E24 in a manner that varies among 168FARN, 4T07, 4T1, 66C14, 67NR and NMuMG cells (right panel).